[Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL].
A new therapeutic strategy for pancreatic cancer is needed because of its very poor prognosis. We presented the results of adoptive immunotherapy and new adoptive immunotherapy using MUC1 specific CTL. We expect that these new strategies may help improve the prognosis of pancreatic cancer.
Masaki
Y
Y
Dept. of Surgery 2, School of Medicine, Yamaguchi University, Japan.
Oka
M
M
D019496:Cancer Vaccines / Q000627:therapeutic use*; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use; D018396:Mucin-1 / Q000276:immunology*; D010190:Pancreatic Neoplasms / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D019496:Cancer Vaccines; D007376:Interleukin-2; D018396:Mucin-1